1. Advani, S. J.; Chung, S. M.; Yan, S. Y.; Gillespie, G. Y.; Markert, J. M.; Whitley, R. J.; Roizman, B.; Weichselbaum, R. R. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 1999, 59, 2055–2058.
2. Skoetz, N.; Will, A.; Monsef, I.; Brillant, C.; Engert, A.; von Tresckow, B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst. Rev. 2017, 5, Cd007941.
3. Watanabe, D.; Goshima, F. Oncolytic virotherapy by HSV. Adv. Exp. Med. Biol. 2018, 1045, 63–84.
4. Masoud, S. J.; Hu, J. B.; Beasley, G. M.; Stewart IV, J. H.; Mosca, P. J. Efficacy of talimogene laherparepvec (T-VEC) therapy in patients with in-transit melanoma metastasis decreases with increasing lesion size. Ann. Surg. Oncol. 2019, 26, 4633–4641.
5. Bai, Y.; Hui, P.; Du, X. Y.; Su, X. Updates to the antitumor mechanism of oncolytic virus. Thorac. Cancer 2019, 10, 1031–1035.